CTLA4 and hepatocellular carcinoma: For example, a phase I/II study showed that combining Tremelimumab (anti‐CTLA‐4 antibody) with Durvalumab (anti‐PD‐L1 antibody) offered better safety and more durable responses in HCC patients compared with either drug alone.225